2m 2m 2m 2m 2m 2m 2m
Madrigal Pharmct (MDGL)
NASDAQ
$512.20-$0.68 (-0.13%)
Price as of Jun 23, 2026 3:29 PM EDT- $11.8BMarket Cap
- 81.24%1-Year Change
- BiotechnologyIndustry
Madrigal Pharmct (MDGL)
$512.20-$0.68 (-0.13%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 958.4M +432.05% | 180.1M N/A | 0 N/A | 0 N/A | |
Cost of Revenue | 56.1M +800.82% | 6.2M N/A | N/A N/A | N/A N/A | |
Gross Profit | 902.3M +418.84% | 173.9M N/A | 0 N/A | 0 N/A | |
Sales and Marketing Expense | 813.8M +87.06% | 435.1M N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -388.5M +64.13% | -236.7M -13.08% | -272.4M +10.96% | -245.4M +19.63% | |
Depreciation and Amortization Expense | 1.5M +37.41% | 1.1M +107.97% | 527,000 +12.85% | 467,000 +15.31% | |
Total Operating Expenses | 1.3B +85.62% | 678.0M +78.19% | 380.5M +29.61% | 293.6M +21.07% | |
Operating Profit | -300.1M -39.72% | -497.9M +30.85% | -380.5M +29.61% | -293.6M +21.07% | |
Interest Income | 37.4M -19.91% | 46.7M +138.30% | 19.6M +796.02% | 2.2M +501.93% | |
Interest Expense | N/A N/A | N/A N/A | -12.7M +220.69% | -4.0M N/A | |
Interest Income and Expense and Net | 37.4M -19.91% | 46.7M +579.49% | 6.9M +485.95% | -1.8M -590.08% | |
Total Nonoperating Income and Expense | -463,000 -101.45% | 32.0M N/A | 0 -100.00% | 4.0M +1,352.01% | |
Income before Taxes | -300.1M -39.72% | -497.9M +30.85% | -380.5M +29.61% | -293.6M +21.07% | |
Income Taxes | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -288.3M -38.12% | -465.9M +24.69% | -373.6M +26.50% | -295.4M +22.12% | |
Net Income from Continuing Operations Applicable to Common | -288.3M -38.12% | -465.9M +24.69% | -373.6M +26.50% | -295.4M +22.12% | |
Basic EPS and Net Income | -12.85 -41.32% | -21.90 +9.55% | -19.99 +16.02% | -17.23 +17.77% | |
Diluted EPS and Net Income | -12.85 -41.32% | -21.90 +9.55% | -19.99 +16.02% | -17.23 +17.77% | |
Basic Weighted Average Shares | 22.4M +5.46% | 21.3M +13.83% | 18.7M +9.05% | 17.1M +3.64% | |
Diluted Weighted Average Shares | 22.4M +5.46% | 21.3M +13.83% | 18.7M +9.05% | 17.1M +3.64% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 198.7M +98.66% | 100.0M +0.10% | 99.9M -69.86% | 331.5M +814.14% | |
Short-Term Investments | 784.9M -5.01% | 826.2M +54.66% | 534.2M +1,862.23% | 27.2M -88.37% | |
Cash and Cash Equivalents and Short-Term Investments | 983.6M +6.19% | 926.3M +46.07% | 634.1M +76.75% | 358.8M +32.71% | |
Total Current Assets | 1.2B +20.61% | 1.0B +62.08% | 637.3M +76.35% | 361.4M +33.01% | |
Accumulated Depreciation | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | 1.5M -31.55% | 2.2M +41.02% | 1.6M +158.40% | 601,000 -29.38% | |
Total Long-Term Assets | 1.5M -31.55% | 2.2M +41.02% | 1.6M +158.40% | 601,000 -29.38% | |
Total Assets | 1.3B +20.85% | 1.0B +62.71% | 640.5M +76.67% | 362.6M +32.65% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | 49.3M N/A | |
Total Current Liabilities | 310.3M +83.30% | 169.3M +42.79% | 118.5M +2.29% | 115.9M +50.83% | |
Total Long-Term Debt | 339.9M +189.09% | 117.6M +1.81% | 115.5M +134.29% | 49.3M N/A | |
Total Long-Term Liabilities | 346.6M +192.28% | 118.6M +1.65% | 116.7M +136.70% | 49.3M +12,636.18% | |
Total Liabilities | 656.9M +128.20% | 287.9M +22.38% | 235.2M +42.40% | 165.2M +113.90% | |
Retained Earnings | -2.1B +16.00% | -1.8B +34.86% | -1.3B +38.81% | -962.7M +44.26% | |
Total Stockholders Equity | 602.7M -20.11% | 754.4M +86.11% | 405.3M +105.35% | 197.4M +0.65% | |
Total Shares Outstanding | 22.8M +3.81% | 22.0M +10.71% | 19.9M +9.79% | 18.1M +5.84% | |
Cash Flow | |||||
Cash from Operating Activities | -189.6M -58.39% | -455.6M +40.51% | -324.2M +44.19% | -224.9M +22.26% | |
Capital Expenditures | 467,000 -68.06% | 1.5M -1.15% | 1.5M +581.57% | 217,000 +3.83% | |
Cash from Investing Activities | 32.3M +111.78% | -274.4M -45.40% | -502.5M -343.13% | 206.7M +4,188.74% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 256.0M -65.18% | 735.1M +23.52% | 595.1M +89.86% | 313.5M +83.05% | |
Financials Ratio | |||||
Gross Margin | 94.14% -2.48% | 96.54% N/A | N/A N/A | N/A N/A | |
Operating Margin | -31.31% -88.67% | -276.39% N/A | N/A N/A | N/A N/A | |
Return on Assets | -25.05% -54.76% | -55.37% -25.67% | -74.49% -19.81% | -92.89% +7.61% | |
Return on Equity | -42.49% -47.12% | -80.35% -35.19% | -123.98% -17.41% | -150.12% +35.34% | |
Revenue Growth | 432.05% N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 4.01 -34.20% | 6.10 +13.51% | 5.38 +72.40% | 3.12 -11.81% | |
Cash Ratio | 0.64 +8.38% | 0.59 -29.89% | 0.84 -70.54% | 2.86 +506.10% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | 0.50 N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | 0.27 N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow